Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ovarian cancer
Biotech
Corcept's phase 3 cancer win sends stock skyrocketing 85%
Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to chemotherapy alone.
Gabrielle Masson
Mar 31, 2025 10:25am
Acrivon stops testing Lilly castoff for ovarian, bladder cancer
Mar 26, 2025 7:05am
Sutro discards CEO, 50% of staff and lead ADC to save cash
Mar 14, 2025 7:05am
Zentalis lays off 40% to fund registrational trial of WEE1 drug
Jan 29, 2025 4:42am
FDA places hold on Zentalis’ WEE1 drug after two sepsis deaths
Jun 18, 2024 8:21am
Genmab inks $1.8B ProfoundBio buyout for would-be Elahere rival
Apr 3, 2024 5:32am
